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Edited by Gianni CesareniAbstract Immunoglobulin A (IgA)-nephropathy (IgAN) is the
most common primary renal glomerular disease in the world that
has no eﬀective treatment. High levels of circulating IgA–ﬁbro-
nectin (Fn) complexes, characteristically found in IgAN patients,
are suggested to cause abnormal deposition of IgA and Fn in
the renal glomeruli of these patients causing renal failure. We
previously reported that binding of Fn to uteroglobin (UG), a
multifunctional anti-inﬂammatory protein, inhibits Fn–IgA
heteromerization. However, the speciﬁc site of Fn–UG interac-
tion until now remained unidentiﬁed. We report here that UG
interacts with the heparin-binding site of Fn and propose that
small molecules competing for interaction with this site may
reduce the level of circulating Fn–IgA complexes in IgAN.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Uteroglobin (UG), also known as Clara cell 10 kDa (CC10)
protein, is the founding member of a newly recognized super-
family of proteins called Secretoglobin [1]. It is a steroid-induc-
ible, multifunctional, secreted protein with potent anti-
inﬂammatory and anti-chemotactic properties [2]. We previ-
ously reported that UG-knockout (UG-KO) mice [3] develop
abnormal deposition of immunoglobulin A (IgA) and ﬁbro-
nectin (Fn) in the renal glomeruli, reminiscent of the patho-
logic ﬁnding characteristic of human IgA-nephropathy
(IgAN) [4]. IgAN is worldwide the most common primary glo-
merular disease that has no eﬀective treatment [5]. It has been
reported that in patients with IgAN high levels of circulating
Fn–IgA complexes are found and these complexes are sug-
gested to play critical roles in the abnormal deposition of
IgA and Fn in the renal glomeruli leading to IgAN pathogen-
esis [6]. Consistent with this ﬁnding, we uncovered that in the
UG-KO mice serum levels of Fn–IgA complexes are also pres-
ent [4]. More importantly, we found that treatment of these
mice with puriﬁed recombinant human UG (hUG) prevents
abnormal glomerular deposition of Fn and IgA [4]. However,
the speciﬁc site of Fn on which UG interacts and the molecular*Corresponding author.
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doi:10.1016/j.febslet.2008.01.025mechanism(s) by which UG suppresses the formation of Fn–
IgA heteromers remain unclear.
Fibronectin (Fn) is a large adhesive glycoprotein composed
of two nearly identical subunits of 220 kDa (reviewed in [7,8]).
Each of these subunits contains a series of functional binding
domains on which several proteins have been reported to inter-
act [9]. Fn is essential for normal growth and development [10]
and it plays critical roles in cell attachment, movement, wound
healing and cancer (for review see [11]). Fn is detectable as a
soluble glycoprotein in blood and other body ﬂuids and an
insoluble form constitutes a major extracellular matrix protein
in tissues.
We previously reported that UG binds Fn and prevents
abnormal glomerular deposition of Fn and IgA [4], a charac-
teristic pathologic ﬁnding in human IgA-nephropathy (IgAN).
We have also reported that UG binds Fn and most likely sup-
presses the formation of Fn–IgA heteromers [4]. However, the
speciﬁc site on Fn with which UG interacts and prevents Fn–
IgA heteromerizaton, until now, remained unclear. The identi-
ﬁcation of this site on Fn may yield valuable information for
the development of small molecules that functionally mimic
UG and prevent Fn–IgA heteromerization. Thus, this site
may be a potential target for developing novel approaches to
reduce the level of circulating Fn–IgA complexes in IgAN.
Accordingly, we carried out experiments to identify and char-
acterize the speciﬁc site(s) on Fn with which UG interacts
forming Fn–UG heteromers.2. Materials and methods
2.1. Reagents
Fn and its peptide fragments were purchased from Sigma and Invitro-
gen, respectively. Puriﬁed secretory IgA from human colostrum and
BSAwere purchased from Sigma (St. Louis, MO). Labeling of recombi-
nant human UG (hUG) was performed by Amersham Radiochemicals.
2.2. Radioiodination of recombinant IgA
This puriﬁed IgA (25 lg) was radioiodinated by using Na125I
(2 mCi; carrier free; 1 Ci = 37 GBq) and Iodo-Beads. The reaction was
carried out in 130 ll of PBS; pH 7.4, at 25 C for 10 min. 125I–IgA was
puriﬁed by Sephdex G-25 spun-column chromatography (1200 · g for
4 min). The column was prewashed with 0.05% bovine serum albumin
(BSA) in PBS. The speciﬁc activity of puriﬁed carrier-free 125I–human
IgA was 20 lCi/lmole.2.3. Preparation of pure recombinant hUG and radiolabeled of hUG
Recombinant hUG was expressed in Escherichia coli and puriﬁed to
homogeneity as previously reported [12]. This protein (25 lg) was radi-
oiodinated using sodium [125I] (2 mCi; carrier free; 1 Ci = 37 GBq) andEuropean Biochemical Societies.
612 B. Chowdhury et al. / FEBS Letters 582 (2008) 611–615IODO-BEADS. The reaction was carried out in 130 ll of phosphate-
buﬀered saline (PBS; pH 7.4) at 25 C for 10 min, and was [125I]-
hUG was puriﬁed by Sephdex G-25 spun-column chromatography
(1200 · g for 4 min). The column was pre washed with 0.05% bovine
serum albumin (BSA) in PBS. The speciﬁc activity of puriﬁed car-
rier-free 125I–hUG was 25 lCi/lmole.
2.4. Ligand aﬃnity chromatography
Fibronectin and its diﬀerent fragments were purchased from Sigma
and Gibco BRL for the preparation of ﬁbronectin Sepharose aﬃnity
column. Fibronectin and its fragments were dialyzed overnight at
4 C against 0.1 M NaHCO3 buﬀer, pH 8.3, containing 0.5 M NaCl
(coupling buﬀer). Fibronectin was then coupled to cyanogen bromide
activated Sepharose-4-B (Pharmica Fine Chemicals, Piscataway, NJ)
according to the manufacturers instructions. Brieﬂy, ﬁbronectin and
its fragments were incubated overnight at 4 C with 0.3 g cyanogen
bromide-activated sepharose, which was pre-washed three times with
1 mM HCl. Active groups were blocked with 0.2 M glycine for 20 h
at 4 C. Excess ligand was removed by alternatively washing the resin
with the coupling buﬀer and 0.1 M Sodium Acetate buﬀer, pH 4.0,
containing 0.5 M NaCl. One hundred microliters of each mixture
containing Fn or its fragments supported with Sepharose-4-B was
incubated with 3H–hUG (2 lCi) under physiological condition in bind-
ing buﬀer in Hanks balance salt solution (HBBS), pH 7.4 containing
0.1% bovine serum albumin in the presence and absence of excess unla-
beled hUG at room temperature for 1 h. The reaction was stopped by
rapid removal of unbound 3H–hUG and the matrix was washed three
times with PBS, pH 7.4. The radioactivity was taken with radioactive
counter.
2.5. Binding of hUG and IgA with Fn aﬃnity column
Binding reactions of hUG or IgA with ﬁbronectin and its fragments
containing diﬀerent binding domain in solution were carried out at
room temperature by mixing 0.5–1.5 pmol of the 125I-ligand (hUG
or IgA; 5–15 · 104 cpm/pmol) with 50 pmol biotinylated Fn and its
fragments in 300 ll of 50 mM sodium phosphate, pH 7.4, containing
100 mMNaCl (PBS) in the absence and presence of varying concentra-
tion of cold ligand during competition studies. After 30 min of incuba-
tion, 1 mg/ml bis(sulfosuccinimidyl) suberate (BS3; Pierce) was added
in the reaction mixture and after another 30 min of incubation, the
cross-linker was inactivated by adding 30 ll of 2 M glycine, pH 7.4.
at room temperature for 30 min. Thereafter, 30 ll of 40 mM BSA
was added. From each reaction vial, 300 ll was transferred to a new
vial containing 10 ll of prepacked streptavidin-conjugated agarose
beads (1.5 mg streptavidin/ml; Pierce) and 50 ll of packed Sepharose
CL-4B (Pharmacia Biotech Inc.). The Sepharose and agarose beads
were preblocked with 2 mg/ml BSA in PBS to reduce the nonspeciﬁc
binding. Binding to the beads was carried out at 4 C over night on
an end-over-end rotator. The reaction was stopped by rapid removal
of unbound radioactive material and the reaction bead was washed
four times with PBS, pH 7.4 containing 0.05% Tween 20. The speciﬁc
binding was calculated by subtracting the non speciﬁc binding from the
total binding. The binding was analyzed by Scatchard plot using the
Ligand computer program.
2.6. In vitro binding of hUG and Fn
Binding studies using recombinant hUG and puriﬁed Fn binding
were also carried out by incubating a mixture of 10 nM puriﬁed
[3H]-hUG (Amersham Radiochemicals) and Fn (100 lg/ml) containing
varying concentrations of unlabeled hUG (0–50 nM) in 50 mM sodium
phosphate buﬀer containing150 mM KCl, pH 7.5, was incubated for
60 min at 4 C in the presence of 10 mM of the crosslinking agen,
DSS (Pierce). The reaction was stopped by adding 1 M Tris–HCl,
pH 6.8 to 1/10 the volume of the reaction mixture and the products
were resolved electrophoresis using a 4–20% SDS gel followed by auto-
radiography using a Cyclone phosphorimager (Packard).
2.7. Statistical analysis
Statistical analyses of the data were performed using Graph Pad
Prism V4.0 software (Graph Pad Software Inc., San Diego, CA) and
Minitab Version 13 (Minitab Inc., State College, PA). P-values
60.05 were considered as statistically signiﬁcant. All experiments were
repeated three times.3. Results and discussion
3.1. Recombinant human UG binds to the heparin-binding site of
ﬁbronectin
Fibronectin consists of type I, type II and type III repeats,
and the variable connecting sequence with several binding do-
mains including those that speciﬁcally bind heparin- and gela-
tin. It has been reported that each of these binding domains
has speciﬁc functional activity [13]. We ﬁrst sought to identify
and characterize the speciﬁc site(s) on Fn with which UG inter-
acts. Accordingly, we ﬁrst carried out binding studies using
[3H] recombinant human UG (hUG) and synthetic peptides
corresponding to various fragments of Fn containing the bind-
ing sites for heparin + gelatin (He + G), heparin (He) only or
gelatin (G) only. The results show that recombinant hUG
interacts with the Fn fragments that contain He + G and He-
binding sites but does not interact with the Fn fragment
containing G-binding site only (Fig. 1A). In order to determine
which of the two sites [i.e. heparin-(He) or gelatin-(G) binding
sites] speciﬁcally interacts with hUG in further detail, we
carried out binding studies using Fn fragments, He + G and
He by incubating each of these fragments with equal amounts
of 3H–hUG followed by addition of increasing concentrations
of non-radioactive hUG for competition. Our results show
that 3H–UG bound to both Fn fragnments is displaced by
unlabeled hUG in a dose-dependent manner (Fig. 1B). These
results show that UG binds to the He-binding site of Fn with
high speciﬁcity. To further conﬁrm whether hUG speciﬁcally
interacts with the He-binding site of Fn, we incubated a ﬁxed
concentrations Fn and 3H–hUG together with increasing con-
centrations of heparin in a competition assay. The results show
that non-radioactive heparin displaces 3H–hUG bound to He
containing fragment of Fn in a dose-dependent manner
(Fig. 1C). These results strongly suggest that hUG speciﬁcally
binds to the heparin-binding site of Fn.
3.2. Binding of UG to the heparin-binding site of Fn is highly
speciﬁc
To further conﬁrm the speciﬁcity of hUG binding to the
heparin-binding site of Fn, we incubated total Fn or its frag-
ments containing either He- or G-binding sites with a speciﬁc
concentration of 3H–hUG together with increasing concen-
trations of non-radioactive hUG. The protein mixture was
resolved by SDS–PAGE under non-denaturing and non-reduc-
ing conditions and radioactive protein bands were detected
using a phosphorimager (Packard). The results show that
radioactive hUG bound to Fn fragment containing He- or
He + G-binding sites (Fig. 1D). Most importantly, non-radio-
active hUG displaced 3H–hUG from the Fn fragment contain-
ing the He-binding site only in a dose-dependent manner
(Fig. 1E), while it failed to displace radioactive hUG from
the Fn-peptide that contained only the G-binding site
(Fig. 1F). Taken together, these results demonstrate that
hUG binds to the heparin-binding site of Fn with high speci-
ﬁcity.
To gather further proof that the interaction of hUG with Fn
indeed requires the heparin-binding site of Fn, we performed
aﬃnity-crosslinking studies using 3H–hUG and non-radioac-
tive Fn as well as Fn-peptide fragment containing only the
(He)-binding site in the presence or absence of varying concen-
trations of non-radioactive hUG. Disuccinimidylsuberate
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Fig. 1. (A) Binding of hUG with Fn and its fragments containing diﬀerent binding domain. One hundred microliters of mixtures containing Fn or its
diﬀerent fragments (Pharmica Fine Chemicals, Piscataway, NJ) containing each of the following binding sites: (He + G)-, (He)- or (G) were
incubated with 3H–hUG (2 lCi) in the binding buﬀer (Hanks Balance Salt Solution, pH 7.4 containing 0.1% bovine serum albumin) at the room
temperature for 1 h. The reaction was stopped by washing three times with 1· PBS, pH 7.4 to remove 3H–hUG. The data are presented as the mean
(n = 3 experiments) ± S.D. (B) Binding of 3H–hUG with the Fn fragment containing (He + G) and (He) sites. Binding studies were performed as
described with varying concentrations of unlabeled hUG (0–50 nM) at room temperature for 1 h. The data are presented as the mean (n = 3
experiments) ± S.D. (C) Binding speciﬁcity of hUG with the Fn fragment containing the (He)-binding site. Binding studies were carried out as
described except that non-radioactive heparin in varying concentrations (0–50 nM) were used for competition with 3H–hUG. The data are from three
experiments, and each data point represents the mean of triplicate determinations. (D) Aﬃnity crosslinking studies. Aﬃnity crosslinking studies were
carried out as described under Section 2. Binding and crosslinking of 3H–hUG–Fn or its fragments containing diﬀerent binding domains are readily
detectable. Lane 1: He + G; lane 2: He only; lane 3: 3H–hUG control; lane 4: Myoglobin (Myg) as a non-speciﬁc control for hUG. (E) Determination
of speciﬁcity of 3H–hUG-binding to (He + G)-binding site of Fn. (He + G) containing fragment of Fn was incubated with a ﬁxed concentration of
3H–hUG and competed with varying concentrations of non-radioactive hUG. Lane 1: control without non-radioactive hUG; lane 2: 2 nM hUG; lane
3: 5 nM hUG; lane 4: 10 nM hUG; lane 5: 25 nM hUG. (F) Non-speciﬁc binding of Fn fragment containing (G)-binding site only. Lane 1: Control
without hUG, lane 2: 5 nM hUG; lane 3: 10 nM hUG; lane 4: 25 nM hUG. (G.) Speciﬁcity of 3H–hUG binding with the (He)-binding site of Fn.
Lane 1: 2 nM hUG; lane 2: 5 nM hUG; lane 3: 10 nM hUG; lane 4: 25 nM hUG; lane 5: 50 nM hUG. (He) = Fn fragment containing the heparin
binding site; (G) = Fn fragment containing the gelatin-binding site; hUG = human uteroglobin.
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protein mixture was resolved by SDS–PAGE under denaturing
and reducing conditions and the radioactive protein bands
were detected by using a phosphorimager. 3H–hUG bound
to the Fn fragment containing the (He)-binding site and this
binding is displaced by non-radioactive hUG in a dose-depen-
dent manner (Fig. 1G, lanes 1–5).
3.3. Fibronectin binds to UG with higher aﬃnity that IgA
We previously reported that Fn–hUG interaction prevents
Fn–IgA heteromerization, reported to be critical for abnormal
accumulation of IgA in the renal glomeruli of IgAN patients
[6] as well as in those of the UG-KO mice [4]. The results of
our present study show that hUG speciﬁcally binds Fn with
its carboxy-terminal heparin-binding domain but not with
the gelatin binding site. Since hUG prevents Fn–IgA hetero-
merization, we sought to determine the aﬃnities of Fn for
binding to hUG and to IgA. Accordingly, we conducted bind-
ing studies using 125I–UG or 125I–IgA and non-radioactive Fn
in presence of increasing concentrations of either non-radioac-tive hUG or IgA. The disassociation constants (Kds) for Fn
binding to IgA and Fn binding to hUG were determined.
The speciﬁc binding of 125I–UG to Fn was saturable
(Fig. 2A) and speciﬁc. Further, the Scatchard analysis of these
data show that there is a single high-aﬃnity binding-site for
hUG on Fn. The calculated apparent dissociation constant
(Kd) for binding of hUG to Fn is 15 nM (Fig. 2B). Similar
experiments conducted with ﬁxed concentration of 125I–IgA
binding to Fn and increasing concentrations of unlabeled
IgA show that binding of 125I–IgA to Fn is also saturable
(Fig. 2C) with a dissociation constant (Kd) of 65 nM
(Fig. 2D). Taken together, these results raise the possibility
that the high-aﬃnity binding of hUG to Fn (Kd = 15 nM)
is eﬀective in preventing the Fn–IgA complex formation,
reported to cause abnormal accumulation of IgA and Fn in
renal glomeruli leading to IgAN.
Several regions of Fn are involved in supporting speciﬁc
biological functions such as cell adhesion, spreading and
migration. In addition, Fn is a major constituent of the
extracellular matrix. In pathologic conditions such as IgAN,
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Fig. 2. (A) Saturation isotherm and Scatchard analysis of 125I–UG binding to Fn. Binding isotherms of hUG to Fn were performed by incubating
increasing concentrations of 125I–UG. Speciﬁc binding (n) was calculated by subtracting nonspeciﬁc binding (.), measured as the residual binding in
the presence of hUG, from the total binding (n). The data shown are the mean of triplicate measurements ± S.D. (B) Scatchard plots of hUG binding
to Fn. The apparent dissociation constant (Kd) estimated from the slope of the line was 15 nM ± 2.6 nM (n = 3). (C) Binding isotherms of IgA to Fn.
Binding isotherms of IgA to Fn were performed by incubating increasing concentration of 125I–IgA. Speciﬁc binding (n) was calculated by
subtracting nonspeciﬁc binding (.), measured as the residual binding in the presence of IgA, from the total binding (n). The data shown are the mean
of triplicate measurements. (D) Scatchard plots of IgA binding to Fn. The apparent dissociation constant (Kd) estimated from the slope of the line was
65 nM ± 5.2 nM (n = 3).
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resulting from excessive circulating Fn–IgA heteromers
appears critical for IgAN pathogenesis [6]. Thus, inhibition
of Fn–IgA heteromerization may facilitate the development
of novel therapeutic strategies for IgAN. In this study, we have
demonstrated that the interaction of Fn with UG occurs on its
heparin binding site. The identiﬁcation of this UG binding site
on Fn not only explains the molecular mechanism by which
UG prevents abnormal deposition of IgA and Fn in the glome-
ruli but also demonstrate that this region of Fn is a potential
target for the development of small molecules that prevent
Fn–IgA heteromerization and prevent IgAN.
It has been reported that recombinant human UG prevents
adhesion and migration of human endothelial cells in vitro by
its speciﬁc interaction with ﬁbronectin [14]. However, the spe-
ciﬁc region(s) of the Fn molecule with which UG interacts and
exerts its biological functions until now remained undeﬁned.
From the perspective of IgAN, identiﬁcation of this site may
allow development of small molecules that competes for inter-
action with this site and prevents the formation of Fn–IgA het-
eromers reported to be associated with IgAN [6,15]. There are
three diﬀerent repeating sequences in each Fn subunit, types I,
II and III. Incorporation of dimeric Fn into extracellular ma-
trix (ECM) requires consecutive binding interactions with it-
self, with integrin receptors, and with various components of
the ECM such as type I collagen (reviewed in [16,17]). There
are also two heparin binding sites (Hep I and Hep II) in the
amino- and carboxy terminal, respectively, of Fn. The hepa-rin-binding domain at the COOH-terminal of Fn binds
CD44 [18], a high aﬃnity receptor for hyaluronan [19]. Ami-
no-terminal heparin binding fragments of Fn stimulates pro-
teoglycan breakdown [19] and release catabolic cytokines
[20]. It has been reported that the 40 kDa COOH-terminal
heparin-binding fragment of Fn binds to CD44 and regulates
MMP gene expression [21]. By competing with CD44 for inter-
action with the heparin-binding site of Fn, hUG may prevent
the release the cytokines that are proinﬂammatory and help to
maintain homeostasis. This may be another mechanism by
which UG exerts its anti-inﬂammatory eﬀects [2].
In summary, we have identiﬁed the speciﬁc site on the Fn
molecule with which UG interacts and suppresses the forma-
tion of Fn–IgA complexes, which are found at a high level in
the circulation of IgAN patients and thought to contribute
of abnormal deposition of IgA and Fn in the renal glomeruli
of the IgAN patients leading to renal failure. Thus, our results
identify a potential drug target for IgAN.
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